RuiYi begins patient dosing in double-blinded trial of gerilimzumab to treat autoimmune disorders

US-based biotechnology firm RuiYi has dosed the first patient in a double-blinded and placebo controlled trial of Gerilimzumab, a new monoclonal antibody, to treat rheumatoid arthritis (RA) and other autoimmune disorders.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news